fashion -WSS

fashion

author：leisure time 2025-10-01 12:34:00 - browse：576

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Disappointing trial forces Pfizer to pivot on obesity medicine plans

leisure time

WSS

Group opposing PBM reform sets lobbying record

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

WHO calls for emergency meeting on new China virus, as cases spread

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

How Medicaid coverage policies for immigrants impact new moms

hotspot

fashion

focus

Alkermes shareholders re

In early work, researchers turn to CRISPR to treat Alzheimer's

Apple is now the first public company to be valued at $3 trillion

Pediatric cancer treatments threatened by a new FDA policy

BioMarin wins approval for gene therapy to treat hemophilia A

As digital health tech proliferates, a new institute aims to cut through hype

ChatGPT in medicine: STAT answers readers' burning questions

ReNAgade cuts staff seven months after raising $300 million

Cancer drug shortages should be causing more outrage

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

focus

Flagship Pioneering launches a new biotech in two countries

Sanders adds drug shortage policies to pandemic preparedness bill

U.K. Biobank has 500,000 peoples' genome sequences available

Diagnostic tests are hitting their mathematical limits

Pediatric cancer treatments threatened by a new FDA policy

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

leisure time

explore

hotspot

hotspot